Format

Send to

Choose Destination
Neurosci Biobehav Rev. 2016 Mar;62:21-34. doi: 10.1016/j.neubiorev.2015.12.010. Epub 2015 Dec 30.

Neuroimaging in moderate MDMA use: A systematic review.

Author information

1
Department of Psychiatry (UPK), University of Basel, Switzerland.
2
Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Switzerland.
3
Department of Psychiatry (UPK), University of Basel, Switzerland. Electronic address: stefan.borgwardt@upkbs.ch.

Abstract

MDMA ("ecstasy") is widely used as a recreational drug, although there has been some debate about its neurotoxic effects in humans. However, most studies have investigated subjects with heavy use patterns, and the effects of transient MDMA use are unclear. In this review, we therefore focus on subjects with moderate use patterns, in order to assess the evidence for harmful effects. We searched for studies applying neuroimaging techniques in man. Studies were included if they provided at least one group with an average of <50 lifetime episodes of ecstasy use or an average lifetime consumption of <100 ecstasy tablets. All studies published before July 2015 were included. Of the 250 studies identified in the database search, 19 were included. There is no convincing evidence that moderate MDMA use is associated with structural or functional brain alterations in neuroimaging measures. The lack of significant results was associated with high methodological heterogeneity in terms of dosages and co-consumption of other drugs, low quality of studies and small sample sizes.

KEYWORDS:

3,4-Methylenedioxymethamphetamine; Adverse effects; Chronic effects; Ecstasy; MDMA; MRI; Moderate use; Neuroimaging; Neurotoxicity

PMID:
26746590
DOI:
10.1016/j.neubiorev.2015.12.010
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center